Clinical Trial: NCT04128501
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | M.D. Anderson Cancer Center |
| Information Provided By: | M.D. Anderson Cancer Center |
| Last Update Posted: | 2026-10-05 |
Study Overview
Brief Summary
This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem cell transplant may help control high risk leukemia and prevent it from coming back after the transplant.
Official Title
Conditions
Intervention / Treatment
- Drug: Azacitidine
- Drug: Venetoclax
Other Study ID Numbers
- 2019-0353
- NCI-2019-06674
- 2019-0353
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | M.D. Anderson Cancer Center |
| Information Provided By: | M.D. Anderson Cancer Center |
| Last Update Posted: | 2026-10-05 |
Study Overview
Brief Summary
This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem cell transplant may help control high risk leukemia and prevent it from coming back after the transplant.
Official Title
Conditions
Intervention / Treatment
- Drug: Azacitidine
- Drug: Venetoclax
Other Study ID Numbers
- 2019-0353
- NCI-2019-06674
- 2019-0353